Strategic alliance extends Coriolis’ Asian market presence

17-Mar-2022

The company will make an equity investment into Japanese service provider U-Medico

Coriolis Pharma has announced a strategic alliance with U-Medico, a formulation development and biophysical characterisations service provider located in Japan, including an equity investment by Coriolis Pharma into U-Medico.

The alliance aims to extend Coriolis’ presence in the Japanese and Asian market, while strengthening U-Medico’s formulation development and biophysical characterisation services, as well as expertise, by giving integrated access to Coriolis’ service portfolio. Together, the companies plan to carry out formulation development as well as biophysical characterisations of biopharmaceuticals and ATMPs, such as viral vectors, and gene- and cell therapies, for clients worldwide.

Researchers from both companies will also exchange scientific knowledge and work together in scientific collaborations, to generate shared expertise and publications.

“U-medico is the leading provider of science-driven formulation development and biophysical characterisation services in Japan and we as Coriolis are proud to become part of it. The strategic alliance is the next step for Coriolis Pharma’s growth strategy based on excellent science.” said Dr Michael Wiggenhorn, CEO of Coriolis Pharma.

Prof Susumu Uchiyama, founder and CSO of U-Medico, already joined Coriolis’ scientific advisory board in September 2021. Prof Uchiyama is also leading the Japanese national project consortium for the development of characterization and quality control of virus vectors for gene therapy.

“This strategic alliance strengthens the scientific collaboration between Coriolis and U-Medico. We are excited to grow together and support our clients with more specialised and high-quality formulation development services,” said Dr Ayano Fukuhara, CEO of U-Medico.

Sign up for your free email newsletter

“In-depth biophysical chemistry knowledge based on high-quality science is essential for the characterisations of biopharmaceuticals and virus vectors. This alliance will definitely contribute to the development of biopharmaceuticals and ATMPs with high quality and safety,” said Prof Susumu Uchiyama.

Companies